The secretary of Health and Human Services nominee wrote in an ethics agreement that he would keep receiving contingency fees.

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by ...

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches ...

Since its launch in 1996, the annual IMD Global Family Business Award has recognized and showcased successful, sustainable, ...

Ozanimod▼ is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active ...

Stargate CEOs cite project’s promise of enabling cancer vaccines, though Musk joins critics in questioning partners’ ...

Merck in Germany was possibly the earliest company ... America's pharmaceutical founding fathers Meanwhile in the USA, Pfizer was founded in 1849 by two German immigrants, initially as a fine ...

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against Prem Watsa’s other long-term stock picks. Prem Watsa is a Canadian billionaire, entrepreneur ...